ABSORB III Confirms Non-inferiority of Bioresorbable Scaffolds
Bioresorbable scaffolds have the potential to overcome many of the limitations of metallic scaffolds such as target lesion failure. The ABSORB III study, comparing an everolimus-eluting bioresorbable vascular (Absorb) scaffold with the everolimus-eluting cobalt-chromium stent has confirmed the non-inferiority of the Absorb scaffold. Interestingly, at the 1-year follow-up, the superiority margin of the trial was not met.
For more, click here